TOP_August2010_FINAL_TOP 8/10/10 2:31 PM Page 5
www.BioOncology.com
Exploring uncharted territories — bringing advances in oncology to light
At Genentech BioOncology, we’re transforming the way cancer is treated by gaining a broad understanding of cancer biology and following a comprehensive approach to drug discovery. A robust pipeline — We currently have 22 new molecules in clinical development across a range of pathways, from angiogenesis to apoptosis. Innovative molecules — Our new molecular entities target the fundamental mechanisms of cancer growth and include antibody-drug conjugates, a HER2 dimerization inhibitor, a potent and specific B-Raf inhibitor, a Hedgehog pathway inhibitor, and antibodies targeting cancer cell-surface antigens. Extensive clinical trial program — We and our partners are currently enrolling patients in over 750 ongoing trials for both postapproval and pipeline products in dozens of tumor types. Our goal is to fundamentally change the way that cancer is treated — not just with incremental advances, but with new standards of care.
© 2010 Genentech USA, Inc. All rights reserved. 10201500 Printed in USA.